Anti-CKAP4/ CLIMP-63/ ERGIC-63 monoclonal antibody

Anti-CKAP4/ CLIMP-63/ ERGIC-63 antibody for FACS & in-vivo assay

Target products collectionGo to CKAP4/CKAP4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0266-Ab-1/ GM-Tg-hg-MP0266-Ab-2Anti-Human CKAP4 monoclonal antibodyHuman
GM-Tg-rg-MP0266-Ab-1/ GM-Tg-rg-MP0266-Ab-2Anti-Rat CKAP4 monoclonal antibodyRat
GM-Tg-mg-MP0266-Ab-1/ GM-Tg-mg-MP0266-Ab-2Anti-Mouse CKAP4 monoclonal antibodyMouse
GM-Tg-cynog-MP0266-Ab-1/ GM-Tg-cynog-MP0266-Ab-2Anti-Cynomolgus/ Rhesus macaque CKAP4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0266-Ab-1/ GM-Tg-felg-MP0266-Ab-2Anti-Feline CKAP4 monoclonal antibodyFeline
GM-Tg-cang-MP0266-Ab-1/ GM-Tg-cang-MP0266-Ab-2Anti-Canine CKAP4 monoclonal antibodyCanine
GM-Tg-bovg-MP0266-Ab-1/ GM-Tg-bovg-MP0266-Ab-2Anti-Bovine CKAP4 monoclonal antibodyBovine
GM-Tg-equg-MP0266-Ab-1/ GM-Tg-equg-MP0266-Ab-2Anti-Equine CKAP4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0266-Ab-1/ GM-Tg-hg-MP0266-Ab-2; GM-Tg-rg-MP0266-Ab-1/ GM-Tg-rg-MP0266-Ab-2;
GM-Tg-mg-MP0266-Ab-1/ GM-Tg-mg-MP0266-Ab-2; GM-Tg-cynog-MP0266-Ab-1/ GM-Tg-cynog-MP0266-Ab-2;
GM-Tg-felg-MP0266-Ab-1/ GM-Tg-felg-MP0266-Ab-2; GM-Tg-cang-MP0266-Ab-1/ GM-Tg-cang-MP0266-Ab-2;
GM-Tg-bovg-MP0266-Ab-1/ GM-Tg-bovg-MP0266-Ab-2; GM-Tg-equg-MP0266-Ab-1/ GM-Tg-equg-MP0266-Ab-2
Products NameAnti-CKAP4 monoclonal antibody
Formatmab
Target NameCKAP4
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CKAP4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CKAP4/ CLIMP-63/ ERGIC-63 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0266
    Target NameCKAP4
    Gene ID10970,216197,362859,702779,481295,101089875,515784,100068385
    Gene Symbol and Synonyms5630400A09Rik,CKAP4,CLIMP-63,CLIMP63,ERGIC-63,LPC-1,p63
    Uniprot AccessionQ07065
    Uniprot Entry NameCKAP4_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseCancer
    Gene EnsemblENSG00000136026
    Target ClassificationTumor-associated antigen (TAA)

    The target: CKAP4, gene name: CKAP4, also named as CLIMP-63, ERGIC-63, p63. Enables RNA binding activity. Located in several cellular components, including lipid droplet; nuclear speck; and rough endoplasmic reticulum. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.